What are the main criteria for pharmaceutical companies to enter into a licensing agreement? How important is the price of the asset? How do they qualify the value they place on an asset they intend to license? In which cases would they choose co-development or joint venture rather than a licensing deal? How important is the size of the company in these strategic decisions? Do medium-sized biotech companies approach these agreements differently when seeking to license? Are there new forms of agreements or methods of managing licensing deals emerging? How can young biotech companies and universities work on the attractiveness of their assets accordingly? What are the legal aspects to be prepared for?
Moderator: Chris Shelley, Partner, Penningtons Manches LLP 
